Skip to main content
. 2022 Apr 25;12(5):389. doi: 10.3390/metabo12050389

Figure 3.

Figure 3

Pathway enrichment analysis of differential metabolites in SCC-9 cells treated with cisplatin. Significantly enriched metabolic pathways (A). Abundance of metabolites in the enriched metabolic pathways (B). SCC9_0, SCC9_1 and SCC9_2 represent the SCC-9 cells treated with cisplatin for 0 h, 24 h or 48 h.